Free Trial

Demant A/S Unsponsored ADR (OTCMKTS:WILYY) Short Interest Update

Demant A/S logo with Medical background

Demant A/S Unsponsored ADR (OTCMKTS:WILYY - Get Free Report) was the target of a large increase in short interest in the month of August. As of August 15th, there was short interest totaling 400 shares, anincreaseof300.0% from the July 31st total of 100 shares. Based on an average daily volume of 1,400 shares, the days-to-cover ratio is presently 0.3 days. Based on an average daily volume of 1,400 shares, the days-to-cover ratio is presently 0.3 days.

Demant A/S Price Performance

Shares of OTCMKTS:WILYY remained flat at $18.99 during trading on Friday. 24 shares of the stock traded hands, compared to its average volume of 426. The company has a 50 day simple moving average of $19.96 and a 200-day simple moving average of $18.93. Demant A/S has a 52-week low of $15.03 and a 52-week high of $21.93. The company has a quick ratio of 1.22, a current ratio of 1.63 and a debt-to-equity ratio of 1.29.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on WILYY shares. Barclays raised shares of Demant A/S from a "strong sell" rating to a "hold" rating in a research report on Friday, June 20th. Citigroup raised shares of Demant A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, June 5th. Two analysts have rated the stock with a Strong Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy".

Check Out Our Latest Stock Report on WILYY

Demant A/S Company Profile

(Get Free Report)

Demant A/S operates as a hearing healthcare and audio technology company in Europe, North America, the Asia Pacific, Asia, and internationally. It operates through two segments: Hearing Healthcare and Communications. The Hearing Healthcare segment is involved in the manufacturing, servicing, and sale of hearing aids, and diagnostic products and services.

See Also

Should You Invest $1,000 in Demant A/S Right Now?

Before you consider Demant A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Demant A/S wasn't on the list.

While Demant A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.